| Nov 20 |
Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
|
| Nov 20 |
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
|
| Nov 15 |
Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes
|
| Nov 13 |
Recursion and Exscientia Shareholders Approve the Proposed Combination
|
| Nov 12 |
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
|
| Nov 10 |
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher
|
| Nov 6 |
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 6 |
Recursion Pharmaceuticals: Q3 Earnings Snapshot
|
| Nov 6 |
Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M
|
| Nov 6 |
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
|
